Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The specific aim of this double blind, randomized phase III trial is to evaluate the safety
and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of
AMS after rapid ascent.